Search results (73)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
Researchers develop new tool to better predict AML outcomes in older patients
17 September 2024
In a study published in the Journal of Clinical Oncology, an international research team has used machine learning to improve risk stratification for patients over 60 diagnosed with acute myeloid leukaemia, an aggressive type of blood cancer.
Oxford Cancer: 5 minutes with Professor Dame Molly Stevens
23 May 2024
Professor Dame Molly Stevens is John Black Professor of Bionanoscience in the Department of Physiology, Anatomy and Genetics and the Institute of Biomedical Engineering. She recently moved her lab from Imperial College London to the University of Oxford and the Kavli Institute for nanoscience discovery, and she is joining the Oxford Cancer community.
OCION Funding Scheme: In conversation with David Church and Luciana Gneo
10 May 2024
The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardees, David Church and Luciana Gneo, to discuss what research the fund will enable them to carry out.
Research team receives $25m Cancer Grand Challenges award
7 March 2024
A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the solid tumours in children challenge.
World Cancer Day: Oxford University professors on the record with their contribution to the fight against cancer
4 February 2024
Principal Investigators at the University talk candidly about their work and how they’re helping the fight against cancer.
AI-based method provides insights for predicting colorectal cancer outcomes
2 February 2024
The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.
Oxford University Hospitals launches new mRNA cancer vaccine trial for patients with head and neck cancers
11 December 2023
The first patient in Oxfordshire has been treated in an mRNA cancer vaccine trial at Oxford University Hospitals NHS Foundation trust (OUH). The trial, led locally by Dr Ketan Shah, consultant clinical oncologist at OUH, marks a significant milestone in the national cancer vaccine advance.
New discovery furthers our understanding of how critical immune cells are controlled during an infection
7 November 2023
A recent publication from Audrey Gérard’s lab looks at how a specific protein, called IFNγ, can coordinate CD8+ T cell responses during a flu infection.
Researchers discover how cancer cells adapt under acidity
30 June 2023
New research led by Dr Johanna Michl and Professor Pawel Swietach has solved the longstanding mystery of how cancer cells are able to maintain a relatively alkaline intracellular pH, despite being surrounded by an acidic environment.
Hypertension drugs could improve cancer immunotherapy efficacy
13 June 2023
Researchers from Oxford's Ludwig Institute for Cancer Research and de Duve Institute have found out that drugs used to treat hypertension could substantially improve the clinical efficacy of cancer immunotherapy. They discovered a new treatment approach that helps T lymphocytes to destroy cancerous cells.
Mitochondrial protein synthesis identified as a potential therapeutic target in lymphoma
8 June 2023
A team led by Alex Clarke at the Kennedy Institute has identified how high mitochondrial activity regulates antibody responses crucial for immunity but is also necessary for the development of lymphoma.
Monica Olcina receives Academy of Medical Sciences Springboard Award
12 May 2023
Monica is one of 40 recipients of the 2023 Springboard Award, which is awarded to biomedical and health researchers in their first independent post to help launch their careers.
The Howat Foundation to fund Chair in Clinical Oncology
10 May 2023
Oxford Cancer is pleased to announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation.
Edward O'Neill wins Prostate Cancer UK Career Acceleration Fellowship
17 April 2023
Dr Edward O'Neill will is to join Oxford University's Nuffield Department of Surgical Sciences after securing a prestigious Prostate Cancer UK Career Acceleration Fellowship.
Four Oxford researchers awarded €2.5 million European Research Council Advanced Grants
12 April 2023
Four University of Oxford researchers have been awarded European Research Council (ERC) Advanced Grants of €2.5 million each over five years to explore their most innovative and ambitious ideas. These grants recognise ground-breaking projects led by researchers with a track record of significant research achievements.
Key exosome subtype in cancer progression identified
8 March 2023
Collaborative work from the Department of Physiology, Anatomy and Genetics and the Department of Oncology has revealed a potential new pathway to block the production of a specific group of exosomes made in the cell’s recycling system that can promote the growth of cancerous tumours.
New research opens new strategies for cancer therapeutics
15 February 2023
Researchers from the Nuffield Department of Medicine’s Target Discovery Institute and CAMS Oxford Institute, and the Department of Biochemistry uncovered at the molecular level how protein BIRC6 (a giant ubiquitin ligase) keeps cells alive.
Oxford Spinouts annouce merger to tackle treatment of cold tumours
16 January 2023
University of Oxford Spinouts 'Celleron Therapeutics' and 'Argonaut Therapeutics' will merge to form IngenOx Therapeutics. The new company will focus on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours.
Improving the sensitivity of therapeutic receptors for cancer therapy
12 January 2023
New research from the Sir William Dunn School of Pathology shows how the effectiveness of therapeutic chimeric antigen receptors might be improved for cancer treatment.
Introducing minimum tumour-free margins in breast cancer surgery may reduce recurrence and improve survival
5 October 2022
A study co-authored by Dr David Dodwell has recommended that surgeons should aim to remove a 1mm wide margin of healthy tissue around a breast tumour to try to reduce the risk of cancer returning and improve breast cancer survival rates worldwide.